Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Subha Nambi
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters; questions recorded in 6).
- Questions
- 7on tracked calls
- Challenge rate
- 0%none of 7 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 6with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 7 of 7 questions from 1 company
ILMNIllumina, Inc.7 questions · 6 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
How are you thinking about the trajectory into second half, especially with the stronger full Q instrument placements
Show response
Ankur said memory cost is in Q2 results, the company secured supply for several quarters, and its instruments use a non-GPU architecture that is more cost-efficient.
Was this at all a function of the market waiting for a more competitive information?
Show response
Jacob attributed elevated placements to Illumina's value proposition, continued X innovation, and a healthy market rather than a one-off catalyst.
Calendar 2026 Q1
Given you have seen 20% of clinical growth for two consecutive quarters now
Show response
Jacob and Ankur said mid-teens clinical growth is strong, higher would be upside, and they see no signs of deceleration.
Calendar 2025 Q4
It appears that 6,000 pull-through is holding up a lot better than expected. Has that leveled off moving forward
Show response
Jacob and Ankur said 6K pull-through persists as customers keep validated assays on it, with the transition substantially complete by end-2026; Europe strong, APAC expected to rebound.
Calendar 2025 Q3
you're expecting a bit of a step-up in Q4 instrument revenue outside China up to $125 million. Do I have that right?
Show response
Jacob called a strong Q4 normal seasonality, not a budget flush; Ankur agreed research pricing headwinds should dissipate post-transition.
Calendar 2025 Q2
is there something in the pipeline that would allow you to be more competitive with a high- throughput platform
Show response
Jacob framed fast turnaround as a NICU niche and emphasized Illumina's focus on highest-quality insight at lowest end-to-end cost for the broader market.
Calendar 2024 Q4
You guys have maintained R&D at just below $1 billion per year. Is that the plan moving forward?
Show response
Jacob defended R&D intensity as tied to the growth roadmap, aiming to grow into a lower percentage rather than cut.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| ILMN Illumina, Inc. | 7 | 0%none of 7 questions |
- ILMNIllumina, Inc. · 7 questions0%none of 7 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 1 | 0%none of 1 question | 1 |
| 2025 Q1 | No questions recorded | — | — |
| 2025 Q2 | 1 | 0%none of 1 question | 1 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
| 2025 Q4 | 1 | 0%none of 1 question | 1 |
| 2026 Q1 | 1 | 0%none of 1 question | 1 |
| 2026 Q2 | 2 | 0%none of 2 questions | 1 |
- 2024 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q1No questions recorded
- 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q41 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2026 Q22 questions · challenge rate 0% (none of 2 questions) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Competitive Dynamics2
- Demand2
- Guidance Reliability2
- Product Launch2
- Innovation & R&D2
- Cost Pressure1
- Supply Chain1
- Revenue Growth1
- Capital Allocation1